Defactinib hydrochloride is under clinical development by Verastem and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Defactinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Defactinib hydrochloride overview

Defactinib hydrochloride (VS-6063) is under development for the treatment of pancreatic ductal adenocarcinoma as adjuvant therapy, metastatic uveal melanoma, KRAS-mutated NSCLC, colorectal cancer, brain metastases from cutaneous melanoma, malignant pleural mesothelioma, pancreatic ductal adenocarcinoma, metastatic adenocarcinoma of the pancreas, endometrial cancer, prostate cancer, epithelial ovarian cancer, fallopian tube cancer, low-grade serous ovarian cancer, peritoneal cancer, triple negative breast cancer, recurrent glioblastoma multiforme, glioblastoma multiforme and pancreatic cancer. The drug candidate is administered by oral route. VS-6063 is a selective inhibitor of the focal adhesion kinase (FAK1) or protein tyrosine kinase 2 (PTK-2). It was also under development for malignant pleural mesothelioma in EU and solid tumors (non-hematologic malignancy).

Verastem overview

Verastem is a development-stage biopharmaceutical company that provides the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Verastem pipeline programs include Avutometinib and Defactinib. The company pipeline is focused on novel small-molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. The company operates in Germany and the US. Verastem is headquartered in Needham, Massachusetts, the US.

For a complete picture of Defactinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.